Stock Target Advisor’s own stock analysis of Adamis Pharmaceuticals is Very Bearish, which is based on 0 positive signals and 9 negative signals. At the last closing, ADMP stock price was USD 0.15. ADMP stock price has changed by -0.01% over the past week, -0.18% over the past month and -85.98% over the last year.
About Adamis Pharma (ADMP:NSD):
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company’s product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
What we like:
There is nothing we particularly like about ADMP stock.
What we don’t like:
Low market capitalization
ADMP stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor risk adjusted returns
Adamis Pharmaceuticals is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for ADMP stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Below median dividend returns
The average income yield of Adamis Pharmaceuticals over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced compared to book value
ADMP stock price is trading high compared to its peers median on a price to book value basis.
Adamis Pharmaceuticals had negative total cash flow in the most recent four quarters.
Negative free cash flow
Adamis Pharmaceuticals had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
ADMP stock has shown below median earnings growth in the previous 5 years compared to its sector
Low Revenue Growth
ADMP stock has shown below median revenue growth in the previous 5 years compared to its sector.